The security IP market is experiencing rapid consolidation and transformation as OEMs increasingly demand fully integrated, certification-ready security components. Providers are shifting from standalone crypto blocks to bundled platforms combining cryptographic libraries, firmware, and Root of Trust modules. Major acquisitions by Synopsys and Cadence, along with differentiation strategies from Rambus, FortifyIQ, and Xiphera around post-quantum cryptography and side-channel protection, are reshaping the competitive landscape.
Synopsys Inc (SNPS)
Synopsys is a provider of electronic design automation software and intellectual property products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Synopsys' comprehensive portfolio is benefiting from a convergence of semiconductor companies moving up the stack of technologies toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Company Info
Highlights
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Synopsys Inc, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Synopsys Inc (SNPS) has returned -17.33% so far this year and -1.75% over the past 12 months. Looking at the last ten years, SNPS has achieved an annualized return of 23.17%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
SNPS
Benchmark (SPY)
Monthly Returns
The table below presents the monthly returns of Synopsys Inc (SNPS) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.89% | -10.13% | -4.09% | -1.82% | ||||||||
| 2025 | 6.36% | -10.63% | -7.49% | 6.72% | 0.33% | 11.47% | 24.40% | -2.27% | -16.24% | -7.15% | -7.49% | 5.32% |
| 2024 | 5.00% | 7.44% | -0.19% | -8.21% | 6.18% | 5.32% | -6.13% | -6.56% | -1.51% | 1.20% | 9.76% | -12.69% |
| 2023 | 9.52% | 2.85% | 6.35% | -3.60% | 22.71% | -2.49% | 4.70% | 2.40% | -0.22% | 1.79% | 15.41% | -5.27% |
| 2022 | -15.43% | 0.18% | 6.82% | -14.07% | 11.39% | -5.68% | 21.59% | -4.98% | -10.48% | -5.26% | 14.15% | -11.94% |
| 2021 | -1.75% | -5.67% | -0.63% | -1.88% | 2.18% | 8.61% | 4.11% | 14.64% | -9.73% | 11.28% | 2.26% | 6.89% |
| 2020 | 5.13% | -7.29% | -6.65% | 27.86% | 17.72% | 7.79% | 2.30% | 10.24% | -3.26% | -1.16% | 5.56% | 14.53% |
| 2019 | 13.33% | 8.74% | 12.70% | 3.94% | -4.02% | 10.42% | 1.04% | 6.34% | -2.02% | -1.29% | 3.40% | -1.83% |
| 2018 | 7.81% | -7.86% | -1.69% | 3.01% | 3.13% | -3.30% | 5.05% | 14.47% | -2.89% | -9.71% | 2.67% | -9.38% |
| 2017 | 6.11% | 13.29% | 0.97% | 1.75% | 1.35% | -2.80% | 4.36% | 4.58% | 0.60% | 7.25% | 3.80% | -5.73% |
| 2016 | -1.49% | 8.73% | 5.25% | 0.48% | 9.15% | 0.66% | 0.02% | 2.08% | 0.58% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Synopsys Inc (SNPS) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of SNPS compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Synopsys Inc volatility is 2.23%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 48.22B | 13.07B | 10.33B | 9.42B | 8.75B | 8.03B | 6.41B | 6.15B | 5.40B | 5.24B | 5.05B | 4.78B | 4.36B | 4.15B | 3.37B |
| Temporary Equity (USD) | - | 30.00M | 31.04M | 38.66M | - | - | - | - | - | - | - | - | - | - | - |
| Equity Attributable To Parent (USD) | 28.33B | 8.99B | 6.15B | 5.52B | 5.30B | 4.91B | 4.08B | 3.48B | 3.28B | 3.20B | 3.13B | 3.06B | 2.79B | 2.50B | 2.10B |
| Equity Attributable To Noncontrolling Interest (USD) | -587.00K | 2.50M | 5.95M | 4.80M | 3.81M | 4.96M | 5.86M | 5.86M | 4.10M | - | - | - | - | 42.29M | - |
| Equity (USD) | 28.33B | 8.99B | 6.15B | 5.52B | 5.30B | 4.91B | 4.09B | 3.49B | 3.28B | 3.20B | 3.13B | 3.06B | 2.79B | 2.54B | 2.10B |
| Redeemable Noncontrolling Interest (USD) | - | 30.00M | 31.04M | 38.66M | - | - | - | - | - | - | - | - | - | - | - |
| Other Non-current Liabilities (USD) | 2.69B | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Long-term Debt (USD) | 13.48B | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Noncurrent Liabilities (USD) | 16.17B | 1.40B | 1.16B | 1.08B | 1.04B | 977.77M | 563.83M | 558.54M | 502.58M | 330.27M | 333.40M | 332.57M | 347.74M | 351.05M | 257.22M |
| Other Current Liabilities (USD) | 2.74B | 1.82B | 2.25B | 2.18B | 1.80B | 1.62B | 1.32B | 1.60B | 1.21B | 1.38B | 1.25B | 1.06B | 911.97M | 922.82M | 763.16M |
| Wages (USD) | 822.58M | 624.82M | 583.85M | 559.89M | 581.69M | 492.63M | 417.16M | 413.31M | 382.77M | 321.43M | 315.08M | 302.30M | 302.37M | 299.96M | 238.69M |
| Accounts Payable (USD) | 164.77M | 207.33M | 155.89M | 37.58M | 27.41M | 30.00M | 19.82M | 85.05M | 19.95M | 13.75M | 9.92M | 28.15M | 8.58M | 29.86M | 6.96M |
| Current Liabilities (USD) | 3.72B | 2.65B | 2.99B | 2.77B | 2.41B | 2.14B | 1.75B | 2.10B | 1.61B | 1.71B | 1.58B | 1.39B | 1.22B | 1.25B | 1.01B |
| Liabilities (USD) | 19.90B | 4.05B | 4.15B | 3.86B | 3.45B | 3.12B | 2.32B | 2.66B | 2.12B | 2.05B | 1.91B | 1.72B | 1.57B | 1.60B | 1.27B |
| Other Non-current Assets (USD) | 28.84B | 5.85B | 5.97B | 5.54B | 5.19B | 4.74B | 3.96B | 3.93B | 3.19B | 3.00B | 2.86B | 2.66B | 2.38B | 2.35B | 1.67B |
| Intangible Assets (USD) | 12.68B | 195.16M | 374.19M | 386.45M | 279.13M | 254.32M | 279.37M | 360.40M | 253.84M | 266.66M | 363.66M | 365.03M | 335.43M | 466.32M | 196.03M |
| Fixed Assets (USD) | 696.69M | 563.01M | 557.26M | 483.30M | 472.40M | 483.82M | 429.53M | 309.31M | 266.01M | 257.04M | 263.08M | 249.10M | 197.60M | 191.24M | 159.52M |
| Noncurrent Assets (USD) | 42.21B | 6.60B | 6.90B | 6.41B | 5.94B | 5.48B | 4.67B | 4.60B | 3.71B | 3.52B | 3.48B | 3.27B | 2.91B | 3.01B | 2.03B |
| Other Current Assets (USD) | 2.69B | 2.06B | 1.51B | 1.24B | 998.53M | 2.36B | 1.60B | 1.42B | 634.24M | 599.62M | 598.87M | - | - | 440.27M | 333.98M |
| Inventory (USD) | 365.19M | 361.85M | 325.59M | 211.93M | 229.02M | 192.33M | 141.52M | 122.41M | - | - | - | - | - | - | - |
| Cash (USD) | 2.96B | 4.05B | 1.59B | 1.57B | 1.58B | - | - | - | 1.05B | 1.12B | 964.94M | - | - | 700.38M | 1.00B |
| Current Assets (USD) | 6.01B | 6.47B | 3.43B | 3.01B | 2.81B | 2.55B | 1.74B | 1.54B | 1.68B | 1.72B | 1.56B | 1.50B | 1.45B | 1.14B | 1.34B |
| Assets (USD) | 48.22B | 13.07B | 10.33B | 9.42B | 8.75B | 8.03B | 6.41B | 6.15B | 5.40B | 5.24B | 5.05B | 4.78B | 4.36B | 4.15B | 3.37B |
News and Insights

Keysight Technologies has surged over 80% in the past 52 weeks, driven by strong demand from AI and defense markets. The company reported 23% revenue growth to $1.6B and raised full-year guidance to 20% growth, with AI currently representing 10% of revenue and defense markets posting record results. However, elevated valuation leaves limited room for execution missteps, with consensus price targets implying only 3-7% upside.

Synopsys announced the launch of its Electronics Digital Twin (eDT) Platform to accelerate software-defined product development, particularly for automotive applications. The platform enables OEMs to complete up to 90% of software validation before hardware availability. The company recently beat earnings expectations with adjusted EPS of $3.77 vs. $3.56 estimate and raised FY2026 guidance. SNPS shares were up 1.57% in premarket trading at $444.07.
Breker Verification Systems appointed Larry Lapides, former Synopsys Executive Director of RISC-V Tools Business Development, to its Advisory Board. Lapides brings extensive EDA industry experience and deep ties to the RISC-V community, supporting Breker's position as a leader in processor verification solutions and standards development.

Synopsys stock fell 3.44% Thursday despite beating Q1 earnings estimates with adjusted EPS of $3.77 and revenue of $2.41 billion. The decline was driven by disappointing guidance, with flat IP revenue sequentially and second-quarter sales guidance below consensus. Analyst Clarke Jeffries cut the price target from $520 to $430, citing underwhelming results and weakness in China revenue due to technology restrictions.

The article highlights that investors are favoring companies combining high earnings growth (20%+) with strong balance sheets in a market with elevated valuations. NVIDIA is noted as one of the fastest-growing large-cap companies driven by AI accelerator demand, while Eli Lilly has delivered robust earnings growth through innovation in therapeutic areas. The article emphasizes that strong financial foundations combined with significant earnings growth signal durable competitive advantages and offer compelling upside potential with resilience.

While Nvidia dominates AI accelerators, the broader AI ecosystem is expanding rapidly with lesser-known companies benefiting from surging AI infrastructure spending. The article highlights four underrated AI stocks: Super Micro Computer (server infrastructure), Arista Networks (cloud networking), Vertiv Holdings (cooling and power management), and Synopsys (semiconductor design software) as compelling alternatives to mega-cap AI plays.
The launch azimuth analysis software market is experiencing rapid growth, expanding from $1.13 billion in 2024 to an anticipated $1.84 billion by 2029 (10.2% CAGR). Growth is driven by rising satellite mega-constellations, commercial space exploration, and AI-driven trajectory optimization. Key players like Airbus, Lockheed Martin, and Northrop Grumman are focusing on real-time trajectory simulations and advanced integrations. Industry consolidation is evident with Synopsys's $35 billion acquisition of Ansys to enhance AI capabilities.
A class action lawsuit has been filed against Synopsys, Inc. alleging that the company made materially false and misleading statements regarding its business operations. The complaint claims Synopsys failed to disclose that its increased focus on AI customers requiring additional customization was deteriorating the economics of its Design IP business, negatively impacting financial results. Investors who purchased Synopsys securities between December 4, 2024 and September 9, 2025 are eligible to participate in the lawsuit.
Grabar Law Office is investigating shareholder claims against four companies for alleged breaches of fiduciary duties and securities fraud. Cytokinetics faces allegations of misleading statements regarding FDA decisions on its aficamten drug application. Molina Healthcare is accused of failing to disclose adverse medical cost trends and guidance cuts. Synopsys allegedly misrepresented financial performance in its ANSYS acquisition materials, with the stock plunging 35.8% after disappointing Q3 results. WEBTOON Entertainment's class action lawsuit survived a motion to dismiss, with allegations of misleading Monthly Active Users metrics at IPO.